Daniel M Bendheim has sold PAHC and made no open-market buys since Aug 2017
EVP, Corporate Strategy at Phibro Animal Health Corporation
SEC CIK 0001601576 · Filings on SEC.gov ↗
$0Bought
$2.9MSold
NoneLast buy
Every filing
10 filings since Aug 2017, newest first
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$306K−100.0%Jan 30
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$237K−100.0%Jan 24
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$242K−100.0%Jan 18
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$162K−100.0%Jan 10
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$238K−100.0%Jan 7
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$111K−100.0%Sep 14
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$927K−100.0%Mar 12
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$159K−100.0%Mar 7
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$199K−100.0%Aug 21
PAHCSell
Phibro Animal Health Corp
EVP, Corporate Strategy
$308K−100.0%Aug 16
Filings come from SEC EDGAR. Not investment advice.